Category and country
Therapeutics companies in Sweden
24 therapeutics profiles in Sweden. Every profile is hand-reviewed with leadership, certifications, and public sources.
Where does therapeutics cluster in Sweden?
Lund (7), Stockholm (7), Gothenburg (2), and Solna (2) Most visible profiles: Biosergen, AnaCardio, Lipum, and Verigraft.
Which standards are already visible?
GMP (1) and GLP (1) Latest review: 22 March 2026. Review cycle: March 2026.
Full list
Therapeutics profiles in Sweden
24 profiles match the active filter.
Current review cycle
Biosergen
SolnaSwedenTherapeutics
Solna biotech company developing innovative antifungal therapeutics for life-threatening invasive fungal infections from a Swedish listed-company base.
- Lead
- Tine Kold OlesenChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
AnaCardio
StockholmSwedenTherapeutics
Stockholm clinical-stage biopharmaceutical company developing novel contractile agents for heart failure from a Swedish operating base.
- Lead
- Patrik StrombergCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Lipum
UmeaSwedenTherapeutics
Umea biopharma company developing first-in-class anti-inflammatory therapeutics for chronic inflammatory disease from its northern Sweden headquarters.
- Lead
- Ola SandborghCEO
- Scale
- Preclinical therapeutics platform
Current review cycle
Verigraft
GothenburgSwedenTherapeutics
Gothenburg regenerative-medicine company developing personalized tissue-engineered grafts and transplantation therapies from an advanced Swedish tissue-therapy platform.
- Lead
- Petter BjorkquistChief Executive Officer
- Scale
- Clinical tissue-therapy platform
Current review cycle
Abera Bioscience
UppsalaSwedenTherapeutics
Uppsala vaccine-development company building next-generation nasal vaccines on an OMV platform, with its own Swedish laboratory and product-development base.
- Lead
- Maria AlrikssonCEO
- Scale
- Development-stage vaccine platform
Current review cycle
Lipigon Pharmaceuticals
UmeaSwedenTherapeutics
Umea therapeutics company focused on lipid-metabolism and severe-dyslipidemia drug development from its northern Sweden research base.
- Lead
- Johan LiwingCEO
- Scale
- Preclinical therapeutics platform
Current review cycle
Elicera Therapeutics
GothenburgSwedenTherapeutics
Gothenburg clinical-stage immuno-oncology company developing cell and gene therapies including CAR-T and armed oncolytic-virus programs from its Swedish base.
- Lead
- Jamal El-MoslehCEO and Co-Founder
- Scale
- Clinical-stage cell and gene therapy platform
Current review cycle
Ascelia Pharma
MalmoSwedenTherapeutics
Malmo biotech company focused on orphan oncology drug development, with global headquarters in southern Sweden and clinical-stage imaging and treatment programs.
- Lead
- Magnus CorfitzenCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Asgard Therapeutics
LundSwedenTherapeutics
Lund immunotherapy company developing direct cell-reprogramming approaches for cancer treatment from the Medicon Village ecosystem.
- Lead
- Cristiana PiresCo-Founder and CEO
- Scale
- Early-stage therapeutics platform
Current review cycle
Affibody
SolnaSwedenTherapeutics
Solna protein-engineering company developing Affibody molecules for targeted therapeutics and molecular imaging from its Swedish operating base.
- Lead
- David BejkerPresident and CEO
- Scale
- Development-stage therapeutics platform
Current review cycle
Diamyd Medical
StockholmSwedenTherapeutics
Stockholm biotech company developing precision immunotherapies for type 1 diabetes, with Swedish clinical-development operations and a linked production footprint in Umea.
- Lead
- Ulf HanneliusPresident and CEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Calliditas Therapeutics
StockholmSwedenTherapeutics
Stockholm specialty-pharma company developing and commercializing therapies for orphan renal and hepatic diseases from its Swedish headquarters.
- Lead
- Renee Aguiar-LucanderCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Orexo
UppsalaSwedenTherapeutics
Uppsala pharmaceutical company developing improved drug products and formulation-based therapeutics, with Swedish R&D and headquarters operations in Uppsala.
- Lead
- Nikolaj SorensenPresident and CEO
- Scale
- Development-stage pharmaceutical platform
Current review cycle
Anocca
SodertaljeSwedenTherapeutics
Sodertalje cell-therapy company building TCR-T cancer programs, in-house manufacturing, and a large engineered-immunity platform from state-of-the-art Swedish facilities.
- Lead
- Reagan JarvisChief Executive Officer, Scientific Founder
- Scale
- Clinical-stage cell-therapy platform
Current review cycle
Xintela
LundSwedenTherapeutics
Lund biopharma company developing stem-cell therapies and targeted oncology assets from Medicon Village, with clinical and GMP-linked advanced-therapy operations.
- Lead
- Evy Lundgren-AkerlundChief Executive Officer
- Scale
- Clinical-stage cell-therapy platform
Current review cycle
Modus Therapeutics
StockholmSwedenTherapeutics
Stockholm biotech company developing sevuparin-based therapeutics for sepsis, severe systemic inflammation, malaria, and related anemia states from a Swedish public-company base.
- Lead
- John OhdChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Alligator Bioscience
LundSwedenTherapeutics
Lund clinical-stage biotech company developing tumor-directed immuno-oncology antibodies, with mitazalimab and related CD40-focused programs at its Swedish headquarters.
- Lead
- Soren BregenholtCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Cantargia
LundSwedenTherapeutics
Lund antibody-therapeutics company developing oncology and inflammation drug candidates from a Swedish clinical-stage biotech platform.
- Lead
- Damian MarronCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Active Biotech
LundSwedenTherapeutics
Lund therapeutics company developing oncology and immunology drug candidates from a Swedish clinical-stage biotech platform.
- Lead
- Helen TornqvistCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Oncopeptides
StockholmSwedenTherapeutics
Stockholm oncology company focused on targeted peptide-drug conjugate therapies and related cancer-treatment programs.
- Lead
- Jakob LindbergCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Hansa Biopharma
LundSwedenTherapeutics
Lund biopharma company developing enzyme-based therapies for transplant medicine, rare immunological diseases, and desensitization treatment.
- Lead
- Soren TulstrupPresident and CEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
BioArctic
StockholmSwedenTherapeutics
Stockholm therapeutics company focused on neurodegenerative diseases, including Alzheimer's and Parkinson's, through antibody and disease-modifying drug programs.
- Lead
- Gunilla OsswaldCEO
- Scale
- Clinical-stage biotech platform
Current review cycle
Camurus
LundSwedenTherapeutics
Lund therapeutic-development anchor built around long-acting drug-delivery technologies and late-stage specialty-pharma execution.
- Lead
- Fredrik TibergPresident and Chief Executive Officer
- Scale
- Late-stage and commercial specialty pharma
Current review cycle
Sobi
StockholmSwedenTherapeutics
Stockholm rare-disease headquarters and technical-operations node used as a Nordic benchmark surface for executive review.
- Lead
- Guido OelkersChief Executive Officer
- Scale
- Global rare-disease operations
Related brief
Read deeper on this category
EU Biotech Regulation 2026: What Changed and Who It Affects
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open briefFAQ
Frequently asked questions on this category
- What does "therapeutics company" mean?
- A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.
- Which European countries lead in therapeutics?
- Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.
- How are therapeutics companies verified in this directory?
- Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.
- Can I compare two therapeutic developers side by side?
- Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.
Next step
Compare companies or open the wider market.
Use the compare tool to view two or three companies side by side, or open the country hub for the full market view.